The COVID-19 pandemic has helped demonstrate the feasibility and benefits of conducting decentralized clinical trials (DCT), but it has not “flipped the switch” on their acceptance by health authorities globally.
Companies interested in decentralized trials – which allow certain activities to be conducted remotely and in or near participants’ homes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?